<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CXCR5 &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cxcr5/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Oct 2026 13:48:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CXCR5 &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Chemokine Receptor CXCR5 Emerges as Tumor-Intrinsic Switch Controlling Chemo-Immunotherapy Response in Triple-Negative Breast Cancer</title>
		<link>https://bioengineer.org/chemokine-receptor-cxcr5-emerges-as-tumor-intrinsic-switch-controlling-chemo-immunotherapy-response-in-triple-negative-breast-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 23 Oct 2026 13:48:16 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Apoptosis]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[CD8+ T cells]]></category>
		<category><![CDATA[CXCL13]]></category>
		<category><![CDATA[CXCR5]]></category>
		<category><![CDATA[immunogenic cell death]]></category>
		<category><![CDATA[p38 MAPK]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[PD-1 blockade]]></category>
		<category><![CDATA[tertiary lymphoid structures]]></category>
		<category><![CDATA[tislelizumab]]></category>
		<category><![CDATA[triple-negative breast cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=449818</guid>

					<description><![CDATA[A new preclinical and retrospective clinical study reports that tumor-intrinsic CXCR5 coordinates CD8-positive T cell recruitment and p38-dependent apoptotic signaling, determining how triple-negative breast cancer responds to paclitaxel plus PD-1 blockade.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">449818</post-id>	</item>
	</channel>
</rss>
